Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that the US Food and Drug Administration (FDA) has approved Susvimo® (ranibizumab injection) 100 mg/mL for the treatment of diabetic macular edema ...

Good (HDL) cholesterol may raise glaucoma risk, while ‘bad’ (LDL) cholesterol could lower the risk of vision loss from ...

The World Health Organization reports that around 2.2 billion people struggle with vision problems such as near-sightedness ...

The new indication adds to the 2021 approval of Susvimo (ranibizumab) for 'wet' or neovascular age-related macular ...

“Good” HDL cholesterol appears to increase risk of glaucoma in people older than 55, researchers reported Feb. 4 in the ...

Use of a sodium-glucose cotransporter 2, or SGLT2, inhibitor combined with calorie restriction resulted in greater rates of type 2 diabetes remission compared with calorie restriction alone, according ...

WATERTOWN, Mass. - EyePoint Pharmaceuticals, Inc. (NASDAQ: NASDAQ:EYPT), currently valued at $535 million, announced positive results from the Phase 2 VERONA clinical trial of DURAVYU™, its ...

What you need to know about the new video connection standards that were announced earlier this year at CES 2025.

A small percentage of patients taking GLP-1 medications have experienced vision problems, but a direct causal link with the ...

A groundbreaking study by the Walter and Eliza Hall Institute employs AI to map retinal thickness, unveiling links to ...

The discovery and development of GLP-1 receptor agonists for type 2 diabetes and obesity is a bench-to-bedside success story.1 Multiple GLP-1 receptor agonists are now in clinical use, such as ...

Researchers have conducted one of the largest eye studies in the world to reveal new insights into retinal thickness, highlighting its potential in the early detection of diseases like type 2 diabetes ...